BioCentury | May 31, 2019
Company News

Vigeo debuts to reprogram tumor microenvironment

...at Boston Children's Hospital. Vigeo's lead candidate, VT1021, is a small cyclic peptide derivative of PSAP...
...been CMO of Verastem Inc. (NASDAQ:VSTM), Bind Therapeutics Inc. and Intellikine Inc. Targets: PSAP - Prosaposin...
BioCentury | Mar 17, 2016
Distillery Therapeutics

Therapeutics: Prosaposin (PSAP); CD36 (GPIV); thrombospondin-1 (TSP-1; THBS1)

...Cancer INDICATION: Ovarian cancer Patient sample, cell culture and mouse studies suggest a PSAP-derived peptide could...
...TSP-1 increased apoptosis compared with vehicle. In a mouse model of CD36-positive ovarian cancer, a PSAP-derived...
...Next steps could include testing efficacy and safety of the peptide in animal models. TARGET/MARKER/PATHWAY: Prosaposin (PSAP)...
BioCentury | Jun 6, 2013
Distillery Therapeutics

Indication: Cancer

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Thrombospondin-1 (TSP-1; THBS1); prosaposin (PSAP) Cell-based...
...cells decreased metastasis compared with transplant of Tsp-1-deficient cells. Injection of a pentapeptide derived from PSAP...
BioCentury | Jul 16, 2009
Distillery Therapeutics

Indication: Cancer

...mice suggests that PSAP could be used to prevent tumor metastases. In cultured tumor-associated fibroblasts, PSAP...
...compared with no treatment. In mice, prostate cancer cells with small hairpin RNA knockdown of PSAP...
...tumors, whereas control prostate cancer cells did not. Next steps include identifying the fragment of PSAP...
BioCentury | Jan 2, 2006
Clinical News

Prosaptide: Development discontinued

...Business: Neurology Molecular target: Not available Description: Peptide derived from the human nerve growth protein prosaposin...
BioCentury | Mar 14, 2005
Clinical News

Prosaptide: Development discontinued

...Business: Neurology Molecular target: Not available Description: Peptide derived from the human nerve growth protein prosaposin...
BioCentury | Mar 12, 2005
Clinical News

Savient to stop Prosaptide Phase II

...pursue other analgesia indications. Prosaptide is a peptide derived from the human nerve growth protein prosaposin. BC...
BioCentury | Jul 26, 2004
Company News

Savient drug delivery, metabolic news

...for severe refractory gout. Prosaptide is a peptide derived from the human nerve growth protein prosaposin...
BioCentury | Aug 4, 2003
Clinical News

Prosaptide: Phase II

...Prosaptide Business: Neurological Molecular target: NA Description: Peptide derived from the human nerve growth protein prosaposin...
BioCentury | Dec 14, 1998
Clinical News

Prosaptide TX14: Myelos began U.S. Phase II placebo-controlled testing

Myelos Neurosciences Corp. , San Diego, Calif. Product: Prosaptide TX14(A) derivative of neurotrophic factor prosaposine Indication: Treat pain syndromes and peripheral neuropathies Status: Myelos began U.S. Phase II placebo-controlled testing in more than 160 patients that...
Items per page:
1 - 10 of 15